Local view for "http://purl.org/linkedpolitics/eu/plenary/2006-03-16-Speech-4-116"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20060316.17.4-116"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
".
I voted in favour of this text.
I am particularly concerned about the growing resistance of bacteria to antibiotics. This poses a real threat. It is advisable, therefore, to increase research in this area and to provide information for patients explaining the dangers of inappropriate use of these medicines.
One of the great advantages of the European Union lies in the exchange of data, and particularly in the area of rare diseases. On this point I expect there to be increased efforts to encourage synergies.
This programme of action is also an opportunity to consider patient mobility. There are some absurd situations in Europe. I met a patient who lives in Strasbourg and who, in order to treat the particular type of cancer from which she is suffering, has to go to Marseille, when the same type of therapy is available five kilometres from her home. That establishment, however, is in Kehl, Germany.
Furthermore, it is essential for funding to be equal to developments.
Finally, there is one point that I cannot support: that is, complementary or alternative medicine. These practices are not medicine, but surely an alternative to medicine. The European Union must focus on the essentials, and it is not appropriate for it to contribute funding to these kinds of practices."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples